May 2013   |   By - Current Partnering

The Cancer Monoclonal Antibody Partnering Agreements report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in cancer monoclonal antibody partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Cancer...

Apr 2013   |   By - Global Markets Direct

Oropharyngeal Cancer – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Oropharyngeal Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Oropharyngeal Cancer, complete with latest updates, and special features on late-stage...

Apr 2013   |   By - Global Markets Direct

Streptococcus Pneumoniae Infection – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Streptococcus Pneumoniae Infection - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Streptococcus Pneumoniae Infection, complete with latest...

Apr 2013   |   By - Global Markets Direct

Influenza B Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Influenza B Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Influenza B Infections, complete with latest updates, and special...

Apr 2013   |   By - Asia Market Information & Development Company

China's demand for alzheimer disease treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical...

Mar 2013   |   By - GlobalData

Aubagio (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Aubagio (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and...

Mar 2013   |   By - GlobalData

Lemtrada (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Lemtrada (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and...

Mar 2013   |   By - GlobalData

Ocrelizumab (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Ocrelizumab (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal...

Mar 2013   |   By - GlobalData

Masitinib (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Masitinib (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection...

Mar 2013   |   By - GlobalData

NU-100 (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “NU-100 (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and...

Mar 2013   |   By - PMR

Central European healthcare receptive to expansion of non-public hospitals Growth in the market for non-public hospitals in the Central European countries of Bulgaria, the Czech Republic, Hungary, Poland, Romania and Slovakia has been curtailed, to a degree, by lack of ability to spend large amounts on private healthcare in these six countries. Populations more commonly use...

Mar 2013   |   By - Technavio

TechNavio's analysts forecast the Global Leukemia Therapeutics market to grow at a CAGR of 10 percent over the period 2012-2016. One of the key factors contributing to this market growth is the significant increase in the number of cancer patients worldwide. The Global Leukemia Therapeutics market has also been witnessing an increase in the number of mergers and acquisitions....

Feb 2013   |   By - Select Biosciences

This is the most up-to-date market report focusing on Cellular Therapy and the HSCT/Cord Blood Market Landscape, published by Select Biosciences.  In this comprehensive market report, we have focused primarily on quantitative market metrics in order to characterize the growth and evolution of the cellular therapy field--in this vein, we present primary industry data that Select...

Jan 2013   |   By - GlobalData

Gastrointestinal Hemorrhage Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Gastrointestinal Hemorrhage Global Clinical Trials Review, H1, 2013" provides data on the Gastrointestinal Hemorrhage clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gastrointestinal...

Jan 2013   |   By - GlobalData

Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2013" provides data on the Non-Alcoholic Steatohepatitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Alcoholic...